Novartis AG (NVS) stock prices updated...
 

Novartis AG stock price

Novartis AG latest news:


  • 12/10/2017 16:13:53

    UPDATE 1-Novartis CAR-T therapy leads to durable response in lymphoma study

    Dec 10 (Reuters) - Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to updated data released at a medical meeting on Sunday.

  • 12/05/2017 15:39:23

    BRIEF-ACCC Institutes Proceedings Against GSK, Novartis

    Australian Competition and Consumer Commission. * INSTITUTED PROCEEDINGS AGAINST GLAXOSMITHKLINE HEALTHCARE AUSTRALIA PTY LTD AND NOVARTIS CONSUMER HEALTH AUSTRALASIA. * PROCEEDINGS ALLEGING THEY MADE FALSE OR MISLEADING REPRESENTATIONS IN MARKETING OF VOLTAREN OSTEO GEL AND VOLTAREN EMULGEL PAIN RELIEF PRODUCTS.

  • 12/05/2017 14:05:51

    BRIEF-Advanced Accelerator Applications Board Recommends $3.9 Bln All Cash Tender Offer By Novartis

    Advanced Accelerator Applications Sa(AAAP) : * ADVANCED ACCELERATOR APPLICATIONS BOARD OF DIRECTORS RECOMMENDS $3.9 BILLION ALL CASH TENDER OFFER BY NOVARTIS. * ADVANCED ACCELERATOR APPLICATIONS (AAAP) - CO'S BOARD RECOMMENDS $3.9 BILLION ALL CASH TENDER OFFER BY NOVARTIS Source text for Eikon: Further company coverage:

  • 11/30/2017 15:29:20

    Mylan shares jump after report Amazon is in talk with generic drug makers

    Shares of drugmaker Mylan NV shot up in the extended session Thursday after a CNBC report that Amazon.com Inc. was holding preliminary talks with generic drugmakers -- including Mylan and Novartis AG unit Sandoz -- as it contemplates entering the pharmacy business. CNBC reported that the talks were high-level, but said Amazon's plans were still not clear. Mylan shares were last up 4.5% after hours, after closing down 0.9%; Novartis shares were up slightly after hours. Speculation about Amazon's entry into the pharmacy business has weighed on pharmaceutical middlemen stocks in recent months. As MarketWatch has reported, Amazon's entry into the field could also have major implications for consumers.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/29/2017 15:06:53

    BRIEF-‍Novartis announces phase three strive data published in NEJM

    Novartis Ag: * ‍NOVARTIS ANNOUNCES PHASE III STRIVE DATA PUBLISHED IN NEJM DEMONSTRATING SIGNIFICANT AND SUSTAINED EFFICACY OF ERENUMAB IN MIGRAINE PREVENTION​. * NOVARTIS - NEJM PUBLISHED POSITIVE RESULTS FROM 6-MONTH PHASE III STRIVE STUDY EVALUATING ERENUMAB IN PREVENTION OF EPISODIC MIGRAINE​. * - ‍ERENUMAB DELIVERED CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT DIFFERENCES FR...

  • 11/13/2017 10:00:00

    Novartis launches heart drug counter-offensive

    ZURICH, Nov 13 (Reuters) - Novartis plans to plow through doubts over its canakinumab drug by asking regulators this year to approve the medicine as a treatment for a group of heart attack survivors that the Swiss drugmaker says is most likely to benefit.

  • 11/10/2017 15:30:23

    Novartis posts eye drug data amid play for Eylea's turf

    Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

  • 10/30/2017 00:18:57

    BRIEF-Advanced Accelerator announces $3.9 bln all cash proposed tender offer by Novartis

    Advanced Accelerator Applications Sa(AAAP). * Advanced accelerator applications announces $3.9 billion all cash proposed tender offer by Novartis. * Novartis will make cash tender offer to acquire all outstanding shares of co, including ADS, for $41 a share and $82 per ADS​. * Deal ‍represents 47 percent premium to 30 volume-weighted trading days prior to unaffected share price on nasdaq on Sept 27.

  • 10/27/2017 16:08:20

    BRIEF-Ophthotech recieves termination notice from Novartis Pharma

    * Ophthotech-On oct 24, co received from Novartis Pharma notice terminating Licensing & Commercialization Agreement between parties dated May 19, 2014 Source text : (http://bit.ly/2gPty5O) Further company coverage:

  • 10/24/2017 01:33:00

    Novartis boosts third-quarter profit, pushes Alcon decision to 2019

    Novartis's third-quarter core net income rose 4 percent at constant currencies, beating expectations.

  • 10/24/2017 00:20:10

    BRIEF-Novartis CEO: Alcon spinoff 'probably direction we are headed' - CNBC

    * Ceo says wants to time alcon exit when market is strong, expects strong market to continue - cnbc

  • 10/24/2017 00:16:55

    BRIEF-Novartis CEO: Novartis shareholders would get Alcon shares in listing

    * CEO Joe Jimenez says expects U.S. price pressure on generics business to remain

  • More trends:

    Novo Nordisk A/SNVO | NOW Inc.DNOW | NQ Mobile Inc.NQ | NRG EnergyNRG | NRG YieldNYLD | NRG YieldNYLD.A | NTT DOCOMODCM | Nu Skin EnterprisesNUS | Nucor CorporationNUE | Nustar Energy L.P.NS |